About TOM1-like protein 2
TOM1-like protein 2 (TOM1L2) is a protein
from Homo sapiens identified by UniProt accession
Q6ZVM7, 507 residues long.
MolForge cross-references it against 0 known binders and
225 disease associations.
Target properties
| Protein name | TOM1-like protein 2 |
| UniProt accession | Q6ZVM7 |
| Gene | TOM1L2 |
| Organism | Homo sapiens |
| Length | 507 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (225)
Diseases linked to this target (Open Targets).
- bone density · score 0.29
- monocyte count · score 0.29
- vital capacity · score 0.28
- systolic blood pressure · score 0.25
- serum alanine aminotransferase measurement · score 0.24
- schizophrenia · score 0.23
- hemoglobin A1 measurement · score 0.21
- autism spectrum disorder · score 0.20
- smoking status measurement · score 0.20
- sex hormone-binding globulin measurement · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6ZVM7-F1 | alphafold | PREDICTED | 69.82 | — |
Amino-acid sequence (507 residues)
MEFLLGNPFS TPVGQCLEKA TDGSLQSEDW TLNMEICDII NETEEGPKDA IRALKKRLNG NRNYREVMLA LTVLETCVKN CGHRFHILVA NRDFIDSVLV KIISPKNNPP TIVQDKVLAL IQAWADAFRS SPDLTGVVHI YEELKRKGVE FPMADLDALS PIHTPQRSVP EVDPAATMPR SQSQQRTSAG SYSSPPPAPY SAPQAPALSV TGPITANSEQ IARLRSELDV VRGNTKVMSE MLTEMVPGQE DSSDLELLQE LNRTCRAMQQ RIVELISRVS NEEVTEELLH VNDDLNNVFL RYERFERYRS GRSVQNASNG VLNEVTEDNL IDLGPGSPAV VSPMVGNTAP PSSLSSQLAG LDLGTESVSG TLSSLQQCNP RDGFDMFAQT RGNSLAEQRK TVTYEDPQAV GGLASALDNR KQSSEGIPVA QPSVMDDIEV WLRTDLKGDD LEEGVTSEEF DKFLEERAKA AEMVPDLPSP PMEAPAPASN PSGRKKPERS EDALFAL
Explore TOM1-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets